研究单位：[1]Eli Lilly and Company[2]Loxo Oncology, Inc.[3]Wannan Medical College Yijishan Hospital,Wuhu,Anhui,China,241001[4]Beijing Cancer hospital,Beijing,Beijing,China,100142[5]Sun Yat-sen University Cancer Center,Guangzhou,Guangdong,China,510060[6]Southern Medical University Nanfang Hospital,Guangzhou,Guangdong,China,510515[7]Hainan Province People's Hospital,Haikou,Hainan,China,570100[8]Affiliated Hospital of Hebei University,Baoding,Hebei,China,071030[9]Xingtai People's Hospital,Xingtai,Hebei,China,054031[10]Harbin Medical University Cancer Hospital,Harbin,Heilongjiang,China,150081[11]The First Affiliated Hospital of Henan University of Science &Technology,Luoyang Shi,Henan,China,471003[12]Henan Cancer Hospital,Zhengzhou,Henan,China,450008[13]Wuhan Union Hospital,Wuhan,Hubei,China,430022[14]Xiangya Hospital Central South University,Changsha,Hunan,China,410008[15]Hunan Cancer Hospital,Changsha,Hunan,China,410013[16]Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School,Nanjing,Jiangsu,China,210000[17]The First Affiliated Hospital of Soochow University,Suzhou,Jiangsu,China,215066[18]The First Hospital of Jilin University,Changchun,Jilin,China,130021[19]Xi'an International Medical Center Hospital,Xi'an,Shaanxi,China,710126[20]Institute of hematology&blood disease hospital,Tianjin,Tianjin,China,300020[21]Tianjin Medical University Cancer Institute and Hospital,Tianjin,Tianjin,China[22]Affiliated Tumor Hospital of Xinjiang Medical University,Urumqi,Xinjiang,China,830002[23]Zhejiang Cancer Hospital,Hangzhou,Zhejiang,China,310022[24]Sichuan Cancer Hospital,Chengdu,China,610041[25]Shanghai East Hospital,Shanghai,China,200120
研究目的：
A study of the safety, side effects, and effectiveness of LOXO-305 in Chinese adults with lymphoma or chronic leukemia who have already had standard of care treatment. Participation could last up to four years.
